Hefei Xingmou Biotechnology Co., Ltd.

Based in Heifei, China, and founded in 2019, Hefei Xingmou Biotechnology Co. , Ltd. operates as a medical company that focuses on gene editing and ophthalmic disease gene therapy services. It covers an area of 1600 square meters, with 30 employees.

The founding team are professors and doctors from the Chinese Academy of Sciences and the Chinese University of Science and Technology. In March 2024, Hefei Xingmou Biotechnology Co. , Ltd. closed a pre-series A+ funding.

In September 2025, Hefei Xingmou Biotechnology Co. , Ltd. closed series A2 funding from returning investor Co-Win Ventures and new investor CAS Venture Capital. Hefei Xingmou Biotechnology Co.

, Ltd. 's main business is the development of ophthalmic gene therapy drugs with AAV vectors. Its core product is RGX-314 for the treatment of wet macular degeneration ophthalmic disease. It has technology platforms such as AAV Dual and Multi-Antibody Platform, AAV Viral Coat Screening Technology Platform, and Gene Editing Technology Platform.

The company generates revenue by selling ophthalmic gene therapy drugs. The series A2 financing will provide important financial support for the company's product R&D, focusing on conducting Phase II clinical trials of the company's core product, the wAMD product XMVA09, as well as simultaneously promoting pharmaceutical, preclinical research and IIT clinical trials of the dAMD pipeline and TED pipeline.